Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease

Ads

You May Also Like

Affimed Reports Financial Results for Fourth Quarter and Year End 2017

Heidelberg, Germany, March 20, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical ...

Horizon Pharma plc to Participate in Upcoming Conferences

DUBLIN, Ireland, May 26, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical ...